GENETIC AND HISTOLOGICAL STUDIES ON EFFECT OF MESENCHYMAL STEM CELL THERAPY ON EXPERIMENTAL RENAL INJURY INDUCED BY CISPLATIN IN MALE ALBINO RATS

Acute kidney injury (AKI) represents a major clinical problem with high mortality and limited treatment protocols. This study was planned to evaluate the therapeutic effectiveness of bone marrow – derived mesenchymal stem cells (BM-MSCs) in a rat model of cisplatininduced AKI. The aim of the present investigation is to determine whether mesenchymal stem cells can restore renal tubular structure and ameliorate cisplatin-induced clastogenesis in the bone marrow cells of rat. The scoring of chromosomal aberrations was undertaken in the current study as markers of clastogenicity. The Study was carried on 36 male white albino rats, of average weight 120-150 gm. The animals were divided into six groups, Group one: - Served as control and received normal saline throughout the experiments. Group two (model control) received a single dose of cisplatin (5 mg/kg interapritoneally) after 5 days. Group three, four, five and six: - Male albino rats with induced ARF received single interapritoneal injection of PKH26 labeled BM-MSCs immediately after induction of renal failure at different time intervals. Serological measurements included serum urea and creatinine, bone marrow preparation for chromosome aberrations were carried out and kidney specimens were processed for H&E. MSCs-treated group exhibited protection against renal injury serologically and histologically. The main result obtained in the present study revealed that cisplatin when given at a single dose of 5 mg/kg cause high incidences of the percentage of total chromosomal aberrations 62.33% and abnormal metaphases in the bone marrow cells of rat. This percentage was reduced nearly to 17.33%